Clinical Case Discussions in C3 Glomerulopathy

Purva Sharma, MD, FACP and Anuja Java, MD, November 6th, 2025 Panel discussion (Brad Dixon, MD, Carla Nester, MD, MSA, FASN, David Kavanagh, BSc, MB, ChB, PhD, FRCP, Miklos Molnar, MD, PhD, John Sperati, MD, MHS) • Choice of treatment and treatment sequencing for C3G in the age of new complement inhibitors and Phase 3 trial results • Role of protocol biopsies, histological recurrence vs clinical signs and timing of treatment • What scenarios (besides insurance coverage) would guide decisions? • Risk of infections (proximal vs terminal and differences between proximal inhibitors)